文献速递心脏核医学

123I-MIBG是比18F-FDG更早的蒽环类心脏毒性标志物:一项临床前SPECT/CT与同步PET/MR研究

[123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study.
PubMed 文献 · EJNMMI Res · 2021-09-20

本研究在阿霉素诱导心脏毒性大鼠模型中纵向比较18F-FDG与123I-MIBG。结果显示123I-MIBG的心/纵隔比值在2周即显著降低,早于4周左室舒张末期容积下降和18F-FDG摄取减低,以及6周左室射血分数降低。心脏神经支配显像应被视为蒽环类心脏毒性的早期关键特征。

要点

  • 123I-MIBG心/纵隔比值在阿霉素处理后2周即显著降低。
  • 18F-FDG心肌摄取在4周和6周降低,且与心脏功能损伤相关。
  • 左室射血分数在6周显著降低(47±6% vs. 70±3%)。

核心结论

  • 阿霉素处理后心脏123I-MIBG摄取在2周即显著降低,早于4周左室舒张末期容积下降和18F-FDG摄取减低,以及6周左室射血分数降低。

研究设计与样本

  • 雄性Wistar Han大鼠静脉给予生理盐水或阿霉素(5 mg/kg),每10天一次共3次。
  • 在首次给药前及之后每2周进行123I-MIBG SPECT/CT和同步18F-FDG PET/7T心脏MR采集,间隔24小时,持续6周。
  • 6周时采集心脏组织进行组织形态学测量。

主要发现

  • 第4周阿霉素组左室舒张末期容积显著降低,第6周维持降低且左室收缩末期容积增加,导致左室射血分数显著降低(47±6% vs. 70±3%)。
  • 第4周和第6周(而非第2周)阿霉素组心肌18F-FDG摄取较对照组降低(第6周分别为4.2±0.5%ID/g和9.2±0.8%ID/g)。
  • 18F-FDG心脏摄取与心脏功能损伤相关。
  • 从第2周起阿霉素组心肌123I-MIBG心/纵隔比值显著降低,并在第4周和第6周维持,第6周降低45.6%。

关键数值与推荐

  • 阿霉素给药方案为5 mg/kg静脉注射,每10天一次共3次。
  • 第6周左室射血分数阿霉素组为47±6%,对照组为70±3%。
  • 第6周心肌18F-FDG摄取阿霉素组为4.2±0.5%ID/g,对照组为9.2±0.8%ID/g。
  • 第6周123I-MIBG心/纵隔比值降低45.6%。

临床怎么用

  • 在蒽环类化疗期间,可考虑将心脏神经支配显像(如123I-MIBG)作为早期心脏毒性的监测手段。
  • 123I-MIBG心/纵隔比值降低可能早于左室容积和射血分数改变,有助于更早识别心脏毒性。

局限性

  • 本研究为临床前大鼠模型,结果外推至临床需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During anthracycline treatment of cancer, there is a lack for biomarkers of cardiotoxicity besides the cardiac dysfunction. The objective of the present study was to compare [18F]FDG and [123I]MIBG (metaiodobenzylguanidine) in a longitudinal study in a doxorubicin-induced cardiotoxicity rat model. METHODS: Male Wistar Han rats were intravenously administered 3 times at 10 days' interval with saline or doxorubicin (5 mg/kg). [123I]MIBG SPECT/CT (single photon emission computed tomography-computed tomography) and simultaneous [18F]FDG PET (positron emission tomography)/7 Tesla cardiac MR (magnetic resonance) imaging acquisitions were performed at 24 h interval before first doxorubicin / saline injection and every 2 weeks during 6 weeks. At 6 weeks, the heart tissue was collected for histomorphometry measurements. RESULTS: At week 4, left ventricle (LV) end-diastolic volume was significantly reduced in the doxorubicin group. At week 6, the decreased LV end-diastolic volume was maintained, and LV end-systolic volume was increased resulting in a significant reduction of LV ejection fraction (47 ± 6% vs. 70 ± 3%). At weeks 4 and 6, but not at week 2, myocardial [18F]FDG uptake was decreased compared with the control group (respectively, 4.2 ± 0.5%ID/g and 9.2 ± 0.8%ID/g at week 6). Moreover, [18F]FDG cardiac uptake correlated with cardiac function impairment. In contrast, from week 2, a significant decrease of myocardial [123I]MIBG heart to mediastinum ratio was detected in the doxorubicin group and was maintained at weeks 4 and 6 with a 45.6% decrease at week 6. CONCLUSION: This longitudinal study precises that after doxorubicin treatment, cardiac [123I]MIBG uptake is significantly reduced as early as 2 weeks followed by the decrease of the LV end-diastolic volume and [18F]FDG uptake at 4 weeks and finally by the increase of LV end-systolic volume and decrease of LV ejection fraction at 6 weeks. Cardiac innervation imaging should thus be considered as an early key feature of anthracycline cardiac toxicity.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Oudot A, Courteau A, Guillemin M, et al. [123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study. EJNMMI Res. 2021. PMID: 34542689. doi:10.1186/s13550-021-00835-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。